Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
Quiz|Articles|February 27, 2026
OncLive Weekly News Quiz (2/27/2026)
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA recently expanded the indication for zongertinib (Hernexeos) in HER2 tyrosine kinase domain (TKD)–mutant, metastatic nonsquamous non–small cell lung cancer (NSCLC). Which of the following best reflects the key clinical implication of the updated data from the phase 1 Beamion LUNG-1 trial (NCT04886804) that supported the accelerated approval?
Advertisement
Related to this article
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Cardiovascular and Bleeding Risk With BTK Inhibitors in CLL
2
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
3
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
4
Expanding Clinical Trial Access Through Community Oncology
5